$RGS

Regis Corporation Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year 2026

REGIS CORP (RGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit No. 99.1 Regis Corporation Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year 2026 Positive Full-Year Same-Store Sales Growth, Including 3.0% at Supercuts Continued Profitability and Positive Cash Flow Support On-Going Efforts to Advance Long-term Gr

Original reporting
Published Sep 1, 2026, 10:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGS
Bearish
medium confidence
Mentioned
$RGS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RGSBearishMed
01

Why it matters

The earnings release highlights a revenue decline and a steep net‑income drop, raising concerns about franchise revenue sustainability.

02

Market read

First‑hand earnings data for a small‑cap consumer discretionary stock; may trigger price movement in pre‑market trading.

03

What to watch

Management is evaluating refinancing options that may improve cost of debt and free cash flow.

Relevance 7/10Novelty 8/10Timing: morning release

Background

Regis Corp (NasdaqGM:RGS) is a haircare franchisor operating Supercuts and other salon brands.

Company-level read

Ticker impact

$RGSBearishMedium confidence
Context

Regis Corp filed an 8‑K reporting Q4 and FY 2026 results, showing revenue decline and a sharp drop in net income year‑over‑year.

Expected impact

potential downside of 4‑6% as investors reassess growth outlook

Evidence & confidence

Revenue fell 4.4 M QoQ and net income collapsed from $116.5 M to $4.4 M in Q4, indicating margin pressure.

Market effects

Haircare and consumer‑discretionary retailers may see heightened scrutiny on franchise revenue models.

U.S. consumer discretionary sector could face modest pressure.

Limited to U.S. small‑cap equity space.

Counterpoint

Cash flow remains positive and same‑store sales grew modestly, which could support a short‑term bounce.

Key entities

  • Regis Corp

    Haircare franchisor reporting FY 2026 results.

  • Susan Lintonsmith

    President and CEO of Regis Corp.

Related articles

$RGSMed

Regis (RGS) Reports $24.4M of Operating Income as Franchise Revenue Falls 12%. Can Company-Owned Salons Offset a Shrinking Franchise Base?

Regis (RGS) reported fiscal 2026 revenue of $224.5M, up from $210.1M, with operating income increasing to $24.4M. Franchise revenue fell 12.1% to $146.2M, while company-owned revenue rose $34.6M to $78.3M. Company-owned same-store sales rose 4.0%, and Adjusted EBITDA improved. Franchise royalties and fees declined, and total locations fell by 229. The company is evaluating refinancing options.

$RGSMedAI 8/10

Regis Corporation Q4 2026 Earnings Call Summary

Regis Corporation reported seven quarters of positive cash flow, with Supercuts driving 3% same-store sales growth. Q4 revenue declined 7.3% due to franchise rental income changes. The company plans to refinance $128M debt, reduce salon closures, and focus on traffic growth. Management expects $7M-$8M debt reduction from excess cash flow. Inflationary pressures are increasing rent costs. Supercuts' growth was driven by pricing, not traffic, which is improving. The company has a $450M NOL carryfo

$RGSMed

Regis Q4 Earnings Call Highlights

Regis reported Q4 net income of $4.4M, down from $116.5M YoY due to prior-year tax benefits. Adjusted EBITDA rose to $32.8M for fiscal 2026, with revenue up $14.4M. The company plans to refinance debt and focus on Supercuts, company-owned salons, and SmartStyle for growth.

$BCPCMedAI 8/10

Balchem Corp (BCPC) Q3 2026 Earnings Call Highlights: Record Revenue, 29th Straight

Balchem Corp (BCPC) reported Q3 2026 record revenue of $291M, up 8.6%, with all segments growing. EBITDA rose 12.4% to $80M, marking 29 straight quarters of growth. The company faces inflationary pressures and seasonality challenges but expects year-over-year growth in Q4. Inventory increased to $177M due to inflation and growth. Clinical trials in Alzheimer's and cardiovascular health show promise, with marketing efforts planned. BCPC's effective tax rate is expected to be 22.5-23%.